Canopy Growth (TSX:WEED; NYSE: CGC) has completed four product transfers of legal cannabis to Ohio-based Battelle, the world’s largest non-profit research and development organization, to support medical research and novel cannabis product development.
Product transfers have consisted of a variety of cannabis forms, including dried cannabis and Canopy’s precisely dosed Softgel capsules.
Battelle is a leader in developing methods for testing a variety of controlled substances as well as employing analytical chemistry services for government and private industry.
“As more states, including Ohio, approve the use of medical cannabis to help individuals with certain illnesses, we believe that Battelle will be able to apply our rigorous and independent research and analysis to advance knowledge and improve safety in what is essentially uncharted territory,” Battelle president and CEO, Lou Von Thaer, said in a statement.
Mark Zekulin, president and co-CEO of Canopy Growth, said the collaboration “offers us a unique ability to advance standardization, intellectual property development and clinical research that can improve the understanding and legal application of cannabis and cannabinoids around the globe.”
